B1851022 - A Phase 3, Open-Label Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 13-valent Pneumococcal Conjugate Vaccine

Grants and Contracts Details

StatusFinished
Effective start/end date9/30/11 → 9/29/14

Funding

  • Pfizer Inc.: $8,940.00